Edick Paul R
Known title: See RemarksCIK: 0001531178
Edick Paul R's purchase track record
How the stock did after each of Edick Paul R's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since November 11, 2021
Stock higher 6 months later
50%
3 months: 50%
Median 6-month return
+5.3%
3 months: +6.0%
Beat the S&P 500
50%
median -0.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/9/2023 | XERS | $24K | -15.7% | +11.9% | +11.8% |
| 12/13/2022 | XERS | $29K | -7.8% | +100.0% | +8.7% |
| 5/12/2022 | XERS | $140K | +19.7% | -1.3% | +0.7% |
| 11/11/2021 | XERS | $461K | +19.7% | -26.9% | -15.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XERS | ▲ Buy | Grant | 1,500,000 | $0 | 1/31/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 10,000 | $24K | 8/9/2023 | View on chart |
| XERS | ▲ Buy | Grant | 750,000 | $0 | 1/31/2023 | View on chart |
| XERS | ▲ Buy | Open Market | 20,000 | $29K | 12/13/2022 | View on chart |
| XERS | ▲ Buy | Open Market | 100,000 | $140K | 5/12/2022 | View on chart |
| XERS | ▲ Buy | Grant | 600,000 | $0 | 1/3/2022 | View on chart |
| XERS | ▲ Buy | Open Market | 20,000 | $46K | 11/15/2021 | View on chart |
| XERS | ▲ Buy | Open Market | 200,000 | $416K | 11/11/2021 | View on chart |
| XERS | ▲ Buy | Grant | 197,231 | — | 10/5/2021 | View on chart |
| XERS | ▲ Buy | Grant | 410,833 | — | 10/5/2021 | View on chart |
| XERS | ▲ Buy | Grant | 13,430 | — | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit
Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit. Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.